Market Research Report
Biomedtracker / Meddevicetracker Q3 2020 Outlook Report
|Published by||Datamonitor Healthcare||Product code||955915|
|Published||Content info||52 Pages
Delivery time: 1-2 business days
|Biomedtracker / Meddevicetracker Q3 2020 Outlook Report|
|Published: July 1, 2020||Content info: 52 Pages||
In this report, we cover catalysts from 27 drugs, devices, diagnostics and deals expected to occur in Q3 2020. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa's drug development benchmarking product utilizing Biomedtracker's LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker. The results of the drug catalysts highlighted in our Biomedtracker / Meddevicetracker Q2 2020 Outlook Report can be found on Page 6. At the end of this report, we have included a list of Large Impact catalysts through Q3 2020.